University of Patras
Ανάπτυξη καινοτόμων νανομορφών για στοχευμένη μεταφορά θεραπευτικών ή/και απεικονιστικών ουσιών στον εγκέφαλο
Abstract
dc:descriptionIn many cases, the delivery of therapeutic and imaging substances to the brain is impossible due to the existence of the blood-brain barrier (BBB). The application of nanotechnology to face this problem has recently begun to show signs of success. Because of the difficulties in neurodegenerative diseases therapeutics and the unmet medical need, a great effort is made in this direction.Recently, the ability of some vesicles produced by cells (extracellular vesicles or exosomes) to selectively transfer their charge to other cells located far away from the parental cells has been demonstrated. Cancer cells in particular produce extracellular vesicles with very good organotropism, which has been shown to play an important role in metastasis.The aim of this dissertation was to investigate the transport mechanisms as well as the important components that determine the organotropic action of cellular vesicles, in order to form the basis for the future development of innovative liposomal forms with increased ability for brain targeting.In the present dissertation, we studied the ability of brain targeting from cellular vesicles (CVs) derived from different cell types (normal, cancer) with different tissue origin, in order to identify the optimal compositions for brain targeting.Initially, cellular vesicles were isolated from human cerebral microvascular epithelial cells (hCMEC/D3) and from mouse skin melanoma cells (B16F10). These vesicles were characterized by size, polydispersity index and ζ-potential, the role of parental cells of CVs on their potential to facilitate delivery of their contents into cells while their ability to be engineered in order to improve their pharmacokinetics has been studied. These vesicles are non-toxic with a size of 100-200nm and a negative surface charge. The results show an increased interaction of homologous CVs with brain cells (hCMEC/D3) in vitro and in vivo, achieving the accumulation of higher amounts in the brain of mice. In addition, the effect of culture media on the targeting capacity of CVs was studied and it was shown that the specific medium for hCMEC/D3 (EndoGRO) produced CVs with a higher brain targeting capacity, compared to CVs grown in the common medium of cells, RPMI. Enrichment of CVs with cholesterol to increase vesicle integrity was only possible on membranes with low cholesterol (hCMEC/D3 CVs). Pegylation and cholesterol enrichment of CVs surface facilitated the delivery of homologous CVs to the brain. In the context of cellular vesicle engineering, the fusion of CVs with PEG-liposomes was also studied. The fusion technique was tested with different types of liposomes and CVs to confirm its functionality. The hybrids between PEG-liposomes and hCMEC CVs, although showing a slightly improved pharmacokinetics relative to the corresponding CVs, failed to replicate the same brain targeting result performed by engineered Chol/PEG CVs. The study of the potential cellular uptake pathway of each vesicle-type has shown that CVs and hybrids interact with cells primarily via the kaveolin pathway, in contrast to the engineered Chol/PEG CVs that use mostly the clathrin pathway.At the same time, the ability to encapsulate innovative neuroprotective and neuroregenerative synthetic microneurotrophins in liposomes was studied. These molecules are quite lipophilic and achieve permeability of BBB. However, their low water solubility and their way of administration, show limitations in their use in therapeutics. Initially, based on the preformulation studies, the optimal lipid compositions and methods for the preparation of liposomal microneurotrophins (BNN27 and BNN237) were determined. Attempts were then made to prepare nanoforms for intranasal administration of BNN27, with the aim of direct brain targeting, addressing the disadvantages of the intravenous route of administration. The coating of liposomes with chitosan, an agent with mucosal properties, was studied, and the optimal composition of BNN27 PC/PG (9/1) liposomes coated with 0.1 w/w chitosan/lipid was determined using chitosan with medium molecular weight as a mucoadhesive polymer. Furthermore, BNN27 nanoemulsions with mucosal agents (chitosan or Carbopol) have been developed as alternative carriers for intranasal administration of BNN27. After appropriate preformulation studies, the optimal BNN27 nanoemulsion compositions were determined. Nanoemulsions with 8% or 10% w/w Capmul MCM and chitosan at 0.3% w/w showed the optimal characteristics of stability and mucoadhesion. Tween80/ Transcutol/ Propylene glycol excipients in a ratio of 4/1/1 were used as a mixture of surfactants. These nanoforms have been characterized for their droplet size, PDI, ζ-potential and morphology. Also, they have been studied in terms of stability of their physicochemical properties, cytotoxicity, permeability of an in vitro ΒΒΒ model, as well as their in vivo fate after intranasal delivery.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kannavou, Maria
- Κανναβού, Μαρία
Subjects
dc:subject × 18- Λιποσώματα
- Κυτταρικά κυστίδια
- Νανογαλακτώματα
- ΒΝΝ27
- Ενδορρινική χορήγηση
- Στόχευση εγκεφάλου
- Μικρονευροτροφίνες
- Liposomes
- Cellular vesicles
- Nanoemulsions
- BNN27
- Intranasal delivery
- Brain targeting
- Microneurotrophins
- Ιατρική Βιοτεχνολογία
- Ιατρική και Επιστήμες Υγείας
- Medical Biotechnology
- Medical and Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/50601